Acceder

K-V Pharmaceutical Co. Opiniones

2,2K respuestas
K-V Pharmaceutical Co. Opiniones
K-V Pharmaceutical Co. Opiniones
Página
46 / 277
#361

Re: K-V Pharmaceutical Co. Opiniones

Poco volumen y poco meneo, seguimos en silencio..........despertara la bestia??

#362

Re: K-V Pharmaceutical Co. Opiniones

esperemos pero vemos caida generalisada en las otc la mas saltante fnma que de 5 se ha ido a 1.7

#363

Re: K-V Pharmaceutical Co. Opiniones

Menudo viajecito fnma!!!! de paracaidas

#364

Re: K-V Pharmaceutical Co. Opiniones

Ricardo mira AONEQ que todavía me estoy dando cabezazos contra la pared. Es un cohete. Míratela Ricardo

#365

Re: K-V Pharmaceutical Co. Opiniones

yo tambien me estoy dando cabesasos y no tengo para comprar

#366

Re: K-V Pharmaceutical Co. Opiniones

zokaira sabes alg nuevo quedice cancun

#367

Re: K-V Pharmaceutical Co. Opiniones

Este comentario es de un mes atras.Solo para q veas q el juez escucha a los Acredors no garantizados, solo q no conozco q abogads representan a los accionistas comunes. De la judge hearing de ayer NO HAYA NADA,en el for/USA.
Opino q los tiBurones estan preparando su estrategia tip FMCC, FNMA, AAMRQ,EKDKQ, digo fuertes subidas con expectaculares caidas
**************************************************************
K-V Could Go in Another Direction to Resolve Plan Disputes
By Stephanie Gleason
NEW YORK--K-V Pharmaceutical Co. (KVPBQ, KVPHQ) was nearing a deal with a committee representing unsecured creditors to resolve objections to the company's bankruptcy-exit plan, but it may go "in another direction altogether," a bankruptcy judge said Wednesday.
Judge Allan Gropper of the U.S. Bankruptcy Court in Manhattan again canceled a hearing that might have allowed K-V Pharmaceutical to begin soliciting votes on its Chapter 11 exit plan after an hour-long meeting with lawyers Wednesday. The hearing is now scheduled for Friday.
"We've made a great deal of progress on many fronts, including resolving many of the objections to the disclosure statement, if not all objections, and have had discussions of a possibility of going in another direction all together," he said.
Judge Gropper added that he expected things to move quickly after Friday "to everyone's benefit, including the benefit of general unsecured creditors," who are currently slated to each receive a slice of $1 million to satisfy their claims.
Hours ahead of the hearing Wednesday afternoon, the pharmaceutical company filed an updated version of its plain-language Chapter 11 exit plan. However, it appears likely after discussions with the judge Wednesday the plan could change again.
The amended plans alter the way convertible noteholder stock is set to be calculated and adds language addressing objections from the committee representing unsecured creditors in the case.
The plan now includes a disclaimer from the committee, stating, "The committee believes that the plan is not in the best interests of holders of general unsecured claims and convertible subordinated notes claims and recommends that holders of general unsecured claims and convertible subordinated notes claims vote to reject the plan."
K-V's currently proposed plan of reorganization is essentially a tiered debt-for-equity sw

#368

Re: K-V Pharmaceutical Co. Opiniones

Este comentario es de un mes atras.Solo para q veas q el juez escucha a los Acredors no garantizados, solo q no conozco q abogads representan a los accionistas comunes. De la judge hearing de ayer NO HAYA NADA,en el foro/USA.
Opino q los tiburones estan preparando su estrategia tipo FMCC, FNMA, AAMRQ,EKDKQ, digo fuertes subidas con expectaculares caidas
**************************************************************
K-V Could Go in Another Direction to Resolve Plan Disputes
By Stephanie Gleason
NEW YORK--K-V Pharmaceutical Co. (KVPBQ, KVPHQ) was nearing a deal with a committee representing unsecured creditors to resolve objections to the company's bankruptcy-exit plan, but it may go "in another direction altogether," a bankruptcy judge said Wednesday.
Judge Allan Gropper of the U.S. Bankruptcy Court in Manhattan again canceled a hearing that might have allowed K-V Pharmaceutical to begin soliciting votes on its Chapter 11 exit plan after an hour-long meeting with lawyers Wednesday. The hearing is now scheduled for Friday.
"We've made a great deal of progress on many fronts, including resolving many of the objections to the disclosure statement, if not all objections, and have had discussions of a possibility of going in another direction all together," he said.
Judge Gropper added that he expected things to move quickly after Friday "to everyone's benefit, including the benefit of general unsecured creditors," who are currently slated to each receive a slice of $1 million to satisfy their claims.
Hours ahead of the hearing Wednesday afternoon, the pharmaceutical company filed an updated version of its plain-language Chapter 11 exit plan. However, it appears likely after discussions with the judge Wednesday the plan could change again.
The amended plans alter the way convertible noteholder stock is set to be calculated and adds language addressing objections from the committee representing unsecured creditors in the case.
The plan now includes a disclaimer from the committee, stating, "The committee believes that the plan is not in the best interests of holders of general unsecured claims and convertible subordinated notes claims and recommends that holders of general unsecured claims and convertible subordinated notes claims vote to reject the plan."
K-V's currently proposed plan of reorganization is essentially a tiered debt-for-equity sw